Literature DB >> 23242671

Shaping of NK cell responses by the tumor microenvironment.

Ana Stojanovic1, Margareta P Correia, Adelheid Cerwenka.   

Abstract

Natural killer (NK) cells belong to the innate immune system and are potent cytolytic and cytokine-producing effector cells in response to tumor targets. NK cell based anti-tumor immunotherapy was so far mainly successful in patients with different types of leukemia. For instance, acute myeloid leukemia (AML) patients displayed a prolonged survival if transplanted with haploidentical stem cells giving rise to NK cells with a mismatch in inhibitory killer immunoglobulin receptors (KIRs) and recipients' HLA class I. Although promising results have been achieved with hematological tumors, solid tumors are in most cases poorly controlled by NK cells. Therapeutic protocols that aimed at improving NK cell responses in patients with solid malignancies succeeded in increasing NK cell numbers and functional responses of NK cells isolated from the patients' peripheral blood. However, in the majority of cases tumor progression and overall survival of patients were not significantly improved. There is increasing evidence that tumor-associated NK cells become gradually impaired during tumor progression compared to NK cells from peripheral blood and healthy tissues. Future protocols of NK cell based immunotherapy should integrate three important aspects to improve NK cell anti-tumor activity: facilitating NK cell migration to the tumor site, enhancing their infiltration into the tumor tissue and ensuring subsequent efficient activation in the tumor. This review summarizes the current knowledge of tumor-infiltrating NK cells and the influence of the tumor microenvironment on their phenotype and function.

Entities:  

Year:  2012        PMID: 23242671      PMCID: PMC3717064          DOI: 10.1007/s12307-012-0125-8

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  121 in total

Review 1.  The roles of IFN gamma in protection against tumor development and cancer immunoediting.

Authors:  Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

2.  Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125.

Authors:  Manish S Patankar; Yu Jing; Jamie C Morrison; Jennifer A Belisle; Frank A Lattanzio; Yuping Deng; Nyet Kui Wong; Howard R Morris; Anne Dell; Gary F Clark
Journal:  Gynecol Oncol       Date:  2005-08-29       Impact factor: 5.482

3.  Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education.

Authors:  Niklas K Björkström; Peggy Riese; Frank Heuts; Sandra Andersson; Cyril Fauriat; Martin A Ivarsson; Andreas T Björklund; Malin Flodström-Tullberg; Jakob Michaëlsson; Martin E Rottenberg; Carlos A Guzmán; Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  Blood       Date:  2010-08-09       Impact factor: 22.113

Review 4.  Oncogenic stress sensed by the immune system: role of natural killer cell receptors.

Authors:  David H Raulet; Nadia Guerra
Journal:  Nat Rev Immunol       Date:  2009-08       Impact factor: 53.106

5.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

6.  Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1.

Authors:  Hequan Li; Yanmei Han; Qiuli Guo; Minggang Zhang; Xuetao Cao
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

7.  Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells.

Authors:  Norman Nausch; Ioanna E Galani; Eva Schlecker; Adelheid Cerwenka
Journal:  Blood       Date:  2008-08-27       Impact factor: 22.113

8.  Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.

Authors:  Alice Hervieu; Cédric Rébé; Frédérique Végran; Fanny Chalmin; Mélanie Bruchard; Pierre Vabres; Lionel Apetoh; François Ghiringhelli; Grégoire Mignot
Journal:  J Invest Dermatol       Date:  2012-09-06       Impact factor: 8.551

9.  Membrane nanotubes facilitate long-distance interactions between natural killer cells and target cells.

Authors:  Anne Chauveau; Anne Aucher; Philipp Eissmann; Eric Vivier; Daniel M Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

10.  The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses.

Authors:  Russell K Pachynski; Brian A Zabel; Holbrook E Kohrt; Nicole M Tejeda; Justin Monnier; Christina D Swanson; Alison K Holzer; Andrew J Gentles; Gizette V Sperinde; Abdolhossein Edalati; Husein A Hadeiba; Ash A Alizadeh; Eugene C Butcher
Journal:  J Exp Med       Date:  2012-07-02       Impact factor: 14.307

View more
  19 in total

Review 1.  Natural killer cell receptors: alterations and therapeutic targeting in malignancies.

Authors:  Gordana Konjević; Ana Vuletić; Katarina Mirjačić Martinović
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

2.  Chemical screening identifies novel small molecule activators of natural killer cell cytotoxicity against cancer cells.

Authors:  Grace Lee; Sheela Karunanithi; Bruce Posner; Hanspeter Niederstrasser; Hong Cheng; Yuriy Federov; Shivaprasad Manjappa; Karam Musaitif; Huaiyu Wang; Zachary Jackson; David Wald
Journal:  Cancer Immunol Immunother       Date:  2021-11-23       Impact factor: 6.630

3.  Exercise: A new role for an old tool.

Authors:  Manja Idorn; Per Thor Straten
Journal:  Mol Cell Oncol       Date:  2016-04-15

4.  Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer.

Authors:  Lei Shi; Kang Li; Yizhan Guo; Anirban Banerjee; Qing Wang; Ulrike M Lorenz; Mahmut Parlak; Lucy C Sullivan; Oscar Okwudiri Onyema; Saeed Arefanian; Edward B Stelow; David L Brautigan; Timothy N J Bullock; Michael G Brown; Alexander Sasha Krupnick
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-31       Impact factor: 11.205

5.  Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells.

Authors:  F Fei; M Lim; A A George; J Kirzner; D Lee; R Seeger; J Groffen; H Abdel-Azim; N Heisterkamp
Journal:  Leukemia       Date:  2014-08-19       Impact factor: 11.528

6.  Inflammasome activation is critical to the protective immune response during chemically induced squamous cell carcinoma.

Authors:  Thais Helena Gasparoto; Carine Ervolino de Oliveira; Luisa Thomazini de Freitas; Claudia Ramos Pinheiro; Juliana Issa Hori; Gustavo Pompermaier Garlet; Karen Angélica Cavassani; Roxana Schillaci; João Santana da Silva; Dario Simões Zamboni; Ana Paula Campanelli
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

Review 7.  Exercise and cancer: from "healthy" to "therapeutic"?

Authors:  Manja Idorn; Per Thor Straten
Journal:  Cancer Immunol Immunother       Date:  2017-03-21       Impact factor: 6.968

Review 8.  Regulation of mTOR, Metabolic Fitness, and Effector Functions by Cytokines in Natural Killer Cells.

Authors:  Sébastien Viel; Laurie Besson; Marie Marotel; Thierry Walzer; Antoine Marçais
Journal:  Cancers (Basel)       Date:  2017-09-28       Impact factor: 6.639

9.  Nidogen-1 is a novel extracellular ligand for the NKp44 activating receptor.

Authors:  Silvia Gaggero; Maurizio Bruschi; Andrea Petretto; Monica Parodi; Genny Del Zotto; Chiara Lavarello; Carola Prato; Laura Santucci; Alessandra Barbuto; Cristina Bottino; Giovanni Candiano; Alessandro Moretta; Massimo Vitale; Lorenzo Moretta; Claudia Cantoni
Journal:  Oncoimmunology       Date:  2018-07-11       Impact factor: 8.110

Review 10.  Monitoring NK cell activity in patients with hematological malignancies.

Authors:  Sébastien Viel; Emily Charrier; Antoine Marçais; Paul Rouzaire; Jacques Bienvenu; Lionel Karlin; Gilles Salles; Thierry Walzer
Journal:  Oncoimmunology       Date:  2013-09-12       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.